Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis

BACKGROUND: Renal anemia is a severe complication of chronic kidney disease (CKD) and may worsen its prognosis. Roxadustat is the only oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that has been proved effective to treat renal anemia. However, effects of roxadustat on non-dial...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Transl Med
Prif Awduron: Jia, Linpei, Dong, Xingtong, Yang, Jingyan, Jia, Rufu, Zhang, Hongliang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AME Publishing Company 2019
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6989965/
https://ncbi.nlm.nih.gov/pubmed/32042736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.12.18
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg